November 14, 2025
Terns Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in London
At Terns, we start with de-risked, clinically validated mechanisms of action and then boldly innovate, aiming to accelerate the development of superior, life-changing small molecule therapies for indications with serious unmet medical needs – all in service of our ultimate goal:
elevating human health.
pipeline
Our lead program TERN-701 is a highly selective, oral, allosteric BCR-ABL inhibitor with a potentially best-in-disease profile that could meaningfully improve upon the efficacy, safety and convenience of existing treatments for chronic myeloid leukemia (CML).
DISCOVER OUR PIPELINE
clinical trials
We’re rapidly advancing clinical programs that matter. We currently have one active study: CARDINAL for chronic myeloid leukemia (currently enrolling).
EXPLORE CLINICAL TRIALS
careers
Our success is built upon exceptional talent. We’re committed to attracting and retaining world-class experts who thrive in our nimble, purpose-driven environment. Join our smart, motivated, experienced team of dedicated scientists and professionals working to have an enduring impact on human health.
VIEW OPEN POSITIONS